key: cord-0742361-mhcv6ko5
authors: Nesbitt, D. J.; Jin, D.; Hogan, J. W.; Chan, P. A.; Simon, M. J.; Vargas, M.; King, E.; Huard, R. C.; Bandy, U.; Hillyer, C. D.; Luchsinger, L. L.
title: Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats
date: 2020-07-26
journal: nan
DOI: 10.1101/2020.07.20.20157743
sha: 15720129ea01919290ace007a55b4041a8a1af97
doc_id: 742361
cord_uid: mhcv6ko5

Epidemic projections and public health policies addressing Coronavirus disease (COVID)-19 have been implemented without data reporting on the seroconversion of the population since scalable antibody testing has only recently become available. We measured the percentage of severe acute respiratory syndrome- Coronavirus-2 (SARS-CoV-2) seropositive individuals from 2,008 blood donors drawn in the state of Rhode Island (RI). We utilized multiple antibody testing platforms, including lateral flow immunoassays (LFAs), enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). We report than an estimated seropositive rate of RI blood donors of approximately 0.6% existed in April-May of 2020. These data imply that seroconversion, and thus infection, is likely not widespread within this population. Daily new case rates peaked in RI in late April 2020. We conclude that IgG LFAs and HTSAs are suitable to conduct seroprevalence assays in random populations. More studies will be needed using validated serological tests to improve the precision and report the kinetic progression of seroprevalence estimates.

The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 pandemic is ongoing, with nearly 36 2.6 million cases and over 128,000 deaths reported from Coronavirus disease (COVID)-19 in the United States 37 to date. 1,2 Transmission models of SARS-CoV-2, based on numerous inferences of other immune responses to 38 viral infections, suggest that infection may provide some immunity to reinfection. 1,3 If true, the utility of 39 serological tests to identify those who have acquired antibodies against SARS-CoV-2 (seroconversion) and the 40 frequency of seroconversion in the population (seroprevalence) is a powerful tool with which to guide public 41 health policies. 4,5 It is critical to determine how many individuals have had COVID-19 and are thus likely to be 42 immune, and differentiate them from those who have not been infected. These data are necessary to inform 43 modeling projections and policy making that will allow an optimal approach to "reopening" a country, state, or 44 region, and furthermore, these data must be accurate and reliable. 45

Serological assays rely on accurate recognition and ideally quantification of antibodies that recognize 46 viral antigens specific to SARS-CoV-2. Optimal test characteristics include high levels of sensitivity and 47 specificity. Coronaviruses have four major structural proteins; spike (S) protein (containing the S1 domain and 48 RBD motif), nucleocapsid (N) protein, membrane (M) protein, and envelop (E) protein. 6 Research conducted on 49 2005 SARS-CoV-1 and Middle East respiratory syndrome Coronavirus (MERS-CoV), which are highly related 50 to SARS-CoV-2, found that recovered individuals produced the strongest immunogenic antibodies against 51 antigens of the S-and N-proteins. 7 Thus, the development of serological tests for SARS-CoV-2 antibodies has 52 focused heavily on the detection of antibodies against these viral proteins. Antibody-based tests vary in both 53 technology (platform) and target antigen (design). In May of 2020, the FDA announced a reversal in its 54 emergency use authorization (EUA) and approval policies in order to help ensure that reliable tests are used to 55 accurately measure seroconversion in a population. Some tests have received EUA but limited data is available. 56

Considerable variability in test characteristics, particularly sensitivity, implies that there may not yet be an ideal 57 test design and instrument platform. This also can lead to variability and potential bias in the estimation of the 58 level of immunity in various locales or subpopulations. 8,9 59 Multiple serological assays have been developed to detect SARS-CoV-2 antibodies from whole blood, 60 plasma and serum. Essentially, three platforms of serological testing have been adopted: 1) in-house enzyme 61 linked immunosorbent assays (ELISA), 2) high-throughput serological assays (HTSA) and 3) lateral flow 62 assays (LFA). ELISAs offer wide flexibility for research laboratories to select virtually any antigenic protein of 63 interest and assay patient sera to provide highly sensitive, quantitative results. HTSAs are more suitable to 64 clinical laboratories processing large volumes of samples. Although HTSAs offer a narrower selection of 65 antigen choices, these platforms offer high-throughput capacity, high sensitivity and can be integrated into 66 clinical lab testing facilities. LFAs also offer limited antigen diversity, but function with small volumes of 67 whole blood, plasma or sera (1 drop, ~20uL) and require short test development times (≤30 minutes) allowing 68 administration and test results at the point of care. As reagent supply, testing capacity and affordability vary 69 across the country, the clinical community will undoubtedly resort to using multiple platforms to fill the 70 demand. 71

Underreporting of COVID-19 cases may be occurring, which could inaccurately reflect the morbidity 72 and mortality of SARS-CoV-2. 10 The objective of this study was to assess the seroprevalence in a sample of 73 blood donors in Rhode Island using commercially available serology tests . 11 To this end, consecutive blood 74 donors were enrolled though the Rhode Island Blood Center (RIBC) into a pilot study with the goal of 75 estimating seroprevalence for the population represented by those who donate blood on a regular basis. This 76 pilot is part of a larger statewide effort to estimate seroprevalence, including a statewide community survey and 77 testing on specific populations of interest. 78

From April 27, 2020 -May 11, 2020, consecutive Rhode Island Blood Center (RIBC) donors (n=2,008) 81 received a 2-question survey and completed a blood or plasma donation. Donor blood samples were then tested 82 using two commercially available serology tests and an in-house ELISA, described below. Plasma or serum was 83 isolated from whole blood samples collected in silica clot activator tubes. Samples were extracted, aliquoted to 84 minimize future freeze-thaw cycles, and stored at -80°C. 85

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2020. 

Flat-well, nickel-coated 96 well ELISA plates (Thermo Scientific; USA) were coated with 2 ug/mL of 99 recombinant S1 spike protein, nucleocapsid protein, or Receptor Binding Domain (RBD) spike protein specific 100 to SARS-CoV-2 in resuspension buffer (1% Human Serum Albumin in 0.01% PBST) and incubated in a 101 stationary humidified chamber overnight at 4°C. On the day of the assay, plates were blocked for 30 min with 102 ELISA blocking buffer (3% W/V non-fat milk in PBST). Standard curves for both S1 and RBD assays were 103 generated by using mouse anti-SARS-CoV spike protein monoclonal antibody (clone [3A2], ABIN2452119, 104

Antibodies-Online) as the standard. Anti-SARS-CoV-2 Nucleocapsid mouse monoclonal antibody (clone [7E1B], 105 bsm-41414M, Bioss Antibodies) was used as a standard for nucleocapsid binding assays. Monoclonal antibody 106 standard curves and serial dilutions of donor sera were prepared in assay buffer (1% non-fat milk in PBST) and 107 added to blocked plates in technical duplicate for 1 hr with orbital shaking at room temperature. Plates were then 108 washed three times with PBST and incubated for 1 hr with ELISA assay buffer containing Goat anti-Human IgA, 109

IgG, IgM (Heavy & Light Chain) Antibody-HRP (Cat. No. ABIN100792, Antibodies-Online) and Goat anti-110

Mouse IgG2b (Heavy Chain) Antibody-HRP (Cat. No. ABIN376251, Antibodies-Online) at 1:30000 and 1:3000 111 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20157743 doi: medRxiv preprint dilutions, respectively. Plates were then washed three times, developed with Pierce TMB substrate for 5 min, and 112 quenched with 3 M HCl. Absorbance readings were collected at 450 nm. Standard curves were constructed in 113 Prism 8.4 (Graphpad Software Inc.) using a Sigmoidal 4PL Non-Linear Regression (curve fit) model. 114

For each assay, seroprevalence was estimated using a Bayesian statistical method that adjusts for 116 sensitivity and specificity of the specific test. The operating characteristics for the Ortho assay were obtained 117 from the technical report distributed by the manufacturer; for SD Biosensor we relied on local validation data. 118

Details described in supplemental methods. 119 120

A total of 2,008 donor samples were collected for this study between April and May of 2020, just as the 122 daily new case rates peaked in RI (https://ri-department-of-health-covid-19-data-rihealth.hub.arcgis.com/). We 123 compared age, sex and race/ethnicity of the sample group to values reported for Rhode Island from the 2010 124 U.S. Census. The median age of donors was 56 years, significantly older than the Rhode Island median age of 125 39.4 years (Fig. 1A, Table 1 ). The sample had ~47% female donors compared to 52% statewide (Fig. 1B , 126 (Fig. 1C, 1D) . Thirteen donors were identified as convalescent plasma or whole blood 132 donors that were aware of their seroconversion status prior to enrollment in the study and were removed from 133 the analysis, which adjusted the total donors analyzed to 1,996. 134

To quantify seroprevalence in this sample, donor samples were tested with an HTSA platform (Ortho 135

Clinical Diagnostics VITROS Total Ig Test) and an LFA platform (SD Biosensor IgM/IgG test). The IgM-only 136 LFA assay yielded 68 positive tests for a 2.7% (95% CI 1.7 to 3.8%) seroconversion ( Fig. 2A, Table 2 ). In 137 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20157743 doi: medRxiv preprint contrast, the IgG-only LFA assay yielded 13 positive tests for 0.6% seroconversion (95% CI 0.3 to 1.1%) and 138 was in agreement with the Ortho HTSA assay, which had 14 positives for a 0.6% seropositivity (95% CI 0.2 to 139 1.1) ( Fig. 2A, Table 2) . 140

In total, 3.9% of all samples (77 seropositive donors) were reactive for at least one test. To report 141 overlap between test results, we constructed a Venn diagram (Fig 2B, Table 2) sensitivity and specificity. Importantly, the reliance on self-reported data must be interpreted with caution, and 152 there was no ability to account for the time since infection, which could impact the sensitivity calculations. 153

The gold-standard in antibody quantification is the ELISA assay for its flexibility in antigen diversity 154 and quantification methodology using monoclonal antibodies to generate standard curves. We designed in-155 house ELISA assays against S1 and NP specific to SARS-CoV-2 antibodies, since these antigens have been 156 described to elicit the most immunogenic response to infection based on SARS-CoV and MERS research. We 157 analyzed all 77 samples that were positive for any serological assay and 30 random samples that were negative 158 for all serological assays as controls for S1 and NP antibodies. Surprisingly, S1 antibody quantification showed 159 a median value of 73.8µg/mL for seropositive samples compared to 45.8µg/mL for seronegative controls (Fig.  160 2C) indicating moderate antibodies against S1 epitopes. Similarly, NP antibody quantification showed a median 161 value of 46.6ng/mL for seropositive samples compared to 31.9ng/mL for seronegative controls, also indicating 162 moderate antibodies against NP epitopes. However, there was ≥100-fold range of antibody values for 163 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20157743 doi: medRxiv preprint seropositive samples in each ELISA test, suggesting that some of the seropositive samples, but not all, were 164 significantly reactive in S1 and NP ELISA, which is highly predictive of neutralizing activity. Correlation 165 analysis of all five tests showed a high degree of positive association between ELISA, HTSAs and IgG LFA 166 tests while IgM LFA test was negatively correlated (Fig. 2E) To investigate this, we subdivided seropositive samples into "IgG/Ortho" or "IgM-only" groups. As 170 expected, the median Ortho HTSA value was 10 4 higher for the IgG/Ortho group than the IgM-only group 171 (134A.U. vs 0.02A.U., respectively) (Fig. 2E) . Similarly, both S1 and NP ELISAs showed significantly higher 172 median antibody concentrations for the IgG/Ortho group than for the IgM-only group (S1; 424.2µg/mL versus 173 60.5µg/mL and NP; 210.1ng/mL versus 39.4ng/mL) (Fig. 2F, 2G) . Importantly, these results conclude that IgG 174 LFA and Ortho HTSA assays, but not the IgM LFA assay, correlate with immunogenic antibodies specific to 175 SARS-CoV-2 as detected by ELISA. 176

Discussion 178 This is among the first studies to evaluate statewide seroprevalence using blood donations. COVID-19 179 antibody testing has entered public discourse as an important metric in determining the population 180 seroprevalence of SARS-CoV-2. Ultimately, the application of antibody testing could be clinically informative 181 as to the degree of immunity afforded incurred by recovered patients or to that of future vaccinated individuals. 182 However, we recognize the limitations of the current study include generalizability and limited demographic 183 and other data of the blood donors that may be important. In fact, seroprevalence has been suggested to be 184 higher in specific racial/ethnic communities based on recent studies. 13 Thus, more inclusive and complete 185 seroprevalence studies will need to be performed in the future. 186

The application of antibody testing could be clinically informative as to the degree of antiviral activity 187 incurred by recovered patients or to that of future vaccinated individuals. Seroprevalence studies have the 188 ability to provide two important metrics: 1) the seroprevalence within a given population and 2) semi-189 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20157743 doi: medRxiv preprint quantification of specific antibodies to SARS-CoV-2 that may correlate with immunity. However, the latter 190 estimation requires that an accurate methodology be adopted at the onset of the study. We recently completed a 191 comprehensive analysis of SARS-CoV-2 serological test characteristics and comparison to antiviral 192 neutralization activity using pseudoviral models. 14 In that investigation, HTSAs were shown to have superior 193 performance characteristics and correlation with neutralizing activity compared to LFAs. It should be noted that 194 the LFAs used in the prior study were different from the LFAs used in this study. 195

Among Rhode Island blood donors, we found the SD Biosensor IgG LFA and the Ortho HTSA assays 196 both reported a ~0.6% estimated seroprevalence rate. This is in agreement with a recent study showing 197 relatively low seroprevalence in many metropolitan areas. 15 It is tempting to speculate that low rates of 198 seroprevalence is a logical result to the social distancing and mitigation policies that have been adopted by 199 virtually the entire world. However, the SD Biosensor IgM LFA assay had very different performance 200 characteristics, did not correlate with ELISA assays and reported a higher seroprevalence rate. The latter 201 approximation would be similar to the Santa Clara seroprevalence rate reported in April of 2020, which found a 202 seroprevalence rate of 2.5-4.2% using LFA assays. 16 However, since the IgM LFA assay correlated poorly with 203 the Ortho HTSA assay, which we have previously shown to associate with neutralization activity and antiviral 204 antibody effectiveness to prevent reinfection of cells with pseudovirus , 14 we conclude the SD Biosensor IgM 205 LFA assay is not informative as to a specific adaptive immune response to SARS-CoV-2. It should be noted 206 that a concurrent SARS-CoV-2 serology study comparing the SD Biosensor LFAs to another LFA and a 207 chemiluminescent assay concluded that the SD Biosensor IgM LFA had limited clinical utility, while the SD 208

Biosensor IgG LFA performed very well across several distinct population sets and compared to the other 209 assays (Dr. Shaolei Lu et al.; manuscript submitted). Our results caution that seroprevalence rates could be 210 miscalculated by as much as 5-fold depending on the type of serology test employed. Only assays that show 211 significant correlation to neutralization activity, a metric of specific adaptive immunity, should be employed to 212 report rates of seroprevalence. 213

LFAs offer the convenience of rapid test results at the point of care and utilization of either whole blood, 214 plasma or serum which makes deployment simple. In this study, we found that the SD Biosensor IgG LFA test 215 provided reliable sensitivity to report seroprevalence. We found in this study that the SD Biosensor IgG LFA 216 test also provided reliable sensitivity to report seroprevalence. However, LFAs do not yield semi-quantitative 217 results which could be used to further understand the immunological range of responses within a study 218 population. Therefore, HTSA platforms are better suited to quantify a wide range of antibody levels in a 219 population while LFAs are suitable for low-cost, rural or studies designed for a limited interpretation of 220 seroprevalence. 221

In conclusion, we find the estimated seroprevalence of Rhode Island blood donors to be relatively low, 222 approximately 0.6%. Thus, we predict undiagnosed and asymptomatic infections are also likely to be low. 223

Considering the possibility that this may be an underestimate of the statewide population, these conclusions 224 draw important findings as it suggests that in the absence of a vaccine, "background" or "herd" immunity to 225 also be low, now four months into the US pandemic, and thus the susceptible population remains at 95% or 226 greater. 227 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20157743 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 26, 2020. . 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 26, 2020. . https://doi.org/10.1101/2020.07.20.20157743 doi: medRxiv preprint

The proximal origin of 229 SARS-CoV-2

A new coronavirus associated with human respiratory disease in China

Early dynamics of transmission and control of COVID-19: a mathematical 233 modelling study

Examination of seroprevalence of coronavirus HKU1 infection with S protein-based 235 ELISA and neutralization assay against viral spike pseudotyped virus

Serological Approaches for COVID-19: 238 Epidemiologic Perspective on Surveillance and Control

B-cell responses in patients who have recovered from severe acute respiratory syndrome 241 target a dominant site in the S2 domain of the surface spike glycoprotein

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: 244 implication for development of RBD protein as a viral attachment inhibitor and vaccine

Efficacy of Serology Testing in Predicting 247 Reinfection in Patients with SARS-CoV-2

Antibody tests for identification of current and past infection with SARS-CoV-2

Correcting under-reported COVID-19 case numbers. medRxiv

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

Validation and Performance Comparison of 257

Three SARS-CoV-2 Antibody Assays. bioRxiv

SARS-CoV-2 Positivity Rate for Latinos in the Baltimore-Washington, DC 259 Region

Serological Analysis of New York City COVID19 Convalescent Plasma Donors. 261 medRxiv

Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States